What Does Tirzepatide Do? Effects, Mechanism & Biomarkers

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Tirzepatide works by activating both GLP-1 and GIP receptors in the brain and pancreas, reducing appetite, slowing gastric emptying, and improving insulin secretion. Clinical trials demonstrate average weight loss of 20–22% over 68 weeks at the highest dose.

Beyond weight loss, tirzepatide improves fasting glucose, HbA1c, and cardiovascular markers in people with type 2 diabetes and obesity. PlexusDx emphasizes understanding your baseline metabolic profile and genetic predispositions to support a more informed treatment conversation with your healthcare provider.

How Tirzepatide Activates Dual Pathways for Metabolic Change

Tirzepatide binds to both GLP-1 and GIP receptors simultaneously, a dual-agonist mechanism distinct from single-agent GLP-1 therapies. This dual activation enhances appetite suppression in the hypothalamus and increases glucose-dependent insulin secretion from pancreatic beta cells.

The GIP pathway component addresses insulin resistance more directly than GLP-1 alone, which may explain tirzepatide's superior glycemic control in trials. Both pathways also slow gastric emptying, prolonging satiety and reducing caloric intake without central nervous system stimulation.

Clinical Outcomes: Weight Loss, Glucose Control, and Cardiovascular Effects

Landmark SURMOUNT trials demonstrated tirzepatide's efficacy across weight loss and metabolic endpoints. The following table summarizes key clinical findings across dosing levels and populations:

Outcome	Evidence Summary
Average Weight Loss (52 weeks)	15% at 5 mg; 22% at 15 mg dose (SURMOUNT-1, placebo-controlled)
HbA1c Reduction (T2D)	1.5–2.0% absolute reduction; superior to GLP-1 monotherapy
Fasting Glucose Improvement	25–35 mg/dL reduction; dose-dependent response
Cardiovascular Safety Signal	Non-inferiority demonstrated; ongoing long-term outcome trials

Individual Biomarkers That May Predict Tirzepatide Response

Baseline metabolic markers including fasting insulin, HOMA-IR, triglycerides, and inflammatory cytokines can provide context for expected tirzepatide efficacy. Individuals with higher baseline insulin resistance may see faster glucose improvements, while those with predominantly appetite-driven obesity may respond more robustly to appetite suppression.

Genetic variants in the GLP1R and GIPR genes affect receptor expression and signaling efficiency. PlexusDx's Precision Peptide Genetic Test identifies predispositions in these pathways to help frame individualized response potential—not to predict exact outcomes, but to support a more targeted provider conversation about treatment expectations.

Safety Considerations and Who Should Evaluate Tirzepatide

Tirzepatide is not appropriate for individuals with personal or family history of medullary thyroid carcinoma, type 1 diabetes, or severe gastroparesis. Nausea, vomiting, and constipation are common early side effects that typically resolve within weeks. Pancreatitis risk is rare but requires immediate medical attention if severe abdominal pain occurs.

Qualification for tirzepatide requires medical evaluation including thyroid history, kidney function, and cardiovascular status. A licensed healthcare provider should assess whether tirzepatide aligns with your clinical profile, medication interactions, and personal risk tolerance before initiating treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's genetic testing reveals predispositions in GLP1R and GIPR pathways—the exact receptors tirzepatide targets. Specific variants like GLP1R rs6923761 and GIPR rs1800437 may help provide context for how your body's receptor signaling capacity could influence treatment response. These insights should be interpreted with a qualified healthcare provider, not as deterministic predictors.

The Precision Peptide Genetic Test identifies your genetic profile across peptide-responsive pathways, including FTO and MC4R variants linked to appetite regulation. This information can support a more personalized conversation about whether tirzepatide's dual mechanism aligns with your underlying metabolic drivers—but genetic predisposition does not guarantee specific outcomes.

When combined with biomarker assessment (fasting glucose, insulin, lipids) and clinical history, genetic pathway data helps your provider frame realistic tirzepatide expectations and monitor for early response signals. PlexusDx emphasizes this genetic-plus-biomarker approach to move beyond standard dosing toward precision-wellness treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.